

Luis Lara-Mejía

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1485925/publications.pdf>

Version: 2024-02-01

12
papers

81
citations

1684188

5
h-index

1474206

9
g-index

12
all docs

12
docs citations

12
times ranked

130
citing authors

#	ARTICLE	IF	CITATIONS
1	Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. <i>Lung Cancer</i> , 2021, 152, 119-126.	2.0	17
2	Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 510-522.	2.6	5
3	Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells. <i>Pathology and Oncology Research</i> , 2021, 27, 597499.	1.9	2
4	Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease. <i>Lung Cancer</i> , 2021, 155, 183-190.	2.0	8
5	RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. <i>BMC Cancer</i> , 2021, 21, 892.	2.6	3
6	Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs. <i>Cancer Biomarkers</i> , 2021, 32, 1-13.	1.7	2
7	Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies. <i>Oncologist</i> , 2021, 26, 1035-1043.	3.7	6
8	Brigatinib in <i>ALK</i> -positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP). <i>Future Oncology</i> , 2021, 17, 169-181.	2.4	5
9	Locoregional control and toxicity after pleurectomy/decortication and intensity-modulated pleural radiation therapy in patients with malignant pleural mesothelioma. <i>Thoracic Cancer</i> , 2020, 11, 3448-3455.	1.9	1
10	Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103033.	4.4	17
11	Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. <i>BMC Cancer</i> , 2020, 20, 829.	2.6	11
12	Carboplatin plus etoposide or topotecan for small-cell lung cancer. <i>Lancet Oncology</i> , The, 2020, 21, 1132-1134.	10.7	4